- Home
- ESPR vs NETD Comparison
ESPR vs NETD Comparison
Compare ESPR & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- NETD
- Stock Information
- Founded
- ESPR 2008
- NETD 2023
- Country
- ESPR United States
- NETD United States
- Employees
- ESPR N/A
- NETD N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- ESPR Health Care
- NETD
- Exchange
- ESPR Nasdaq
- NETD Nasdaq
- Market Cap
- ESPR 399.0M
- NETD 409.1M
- IPO Year
- ESPR 2013
- NETD 2023
- Fundamental
- Price
- ESPR $2.30
- NETD $10.80
- Analyst Decision
- ESPR Buy
- NETD
- Analyst Count
- ESPR 5
- NETD 0
- Target Price
- ESPR $7.30
- NETD N/A
- AVG Volume (30 Days)
- ESPR 8.8M
- NETD 28.2K
- Earning Date
- ESPR 11-07-2024
- NETD 01-01-0001
- Dividend Yield
- ESPR N/A
- NETD N/A
- EPS Growth
- ESPR N/A
- NETD N/A
- EPS
- ESPR N/A
- NETD 0.45
- Revenue
- ESPR $295,451,000.00
- NETD N/A
- Revenue This Year
- ESPR $186.90
- NETD N/A
- Revenue Next Year
- ESPR $31.10
- NETD N/A
- P/E Ratio
- ESPR N/A
- NETD $24.04
- Revenue Growth
- ESPR 187.12
- NETD N/A
- 52 Week Low
- ESPR $1.58
- NETD $10.37
- 52 Week High
- ESPR $3.94
- NETD $10.80
- Technical
- Relative Strength Index (RSI)
- ESPR 44.79
- NETD 75.54
- Support Level
- ESPR $2.12
- NETD $10.77
- Resistance Level
- ESPR $2.54
- NETD $10.79
- Average True Range (ATR)
- ESPR 0.35
- NETD 0.01
- MACD
- ESPR -0.10
- NETD 0.00
- Stochastic Oscillator
- ESPR 21.90
- NETD 100.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.